


Jeremy Powell
Technology Appraisal Project Manager
National Institute for Health and Clinical Excellence
MidCity Place
71 High Holborn
London
WC1V 6NA

From The Registrar

@rcplondon.ac.uk

20 July 2011

Dear Mr Powell

Re: Cetuximab, bevacizumab and panitumumab monotherapy for the treatment of metastatic colorectal cancer that has progressed after first line chemotherapy (review of technology appraisal 150 and part-review of technology appraisal 118) – Assessment Report

The Royal College of Physicians (RCP) plays a leading role in the delivery of high quality patient care by setting standards of medical practice and promoting clinical excellence. We provide physicians in the United Kingdom and overseas with education, training and support throughout their careers. As an independent body representing over 25,000 Fellows and Members worldwide, we advise and work with government, the public, patients and other professions to improve health and healthcare.

I write on behalf of the NCRI/RCP/RCR/ACP/JCCO who are grateful for the opportunity to jointly respond to this consultation. Our experts found the report to both comprehensive and objective and have not raised any areas of concern. However, as this is a substantial document, we feel that steps could be taken to add to its utility by making it more reader-friendly. This could be achieved by producing an abbreviated version with the key points highlighted.

Yours sincerely